June 10, 2021 08:00 AM EDTUpdated 10:45 AM
Financing

Syn­thekine nabs megaround in bid to edge out Mer­ck, Sanofi in IL-2 sprint

Jason Mast

Editor

Nine months af­ter launch­ing out of Stan­ford with $82 mil­lion and a port­fo­lio of en­gi­neered cy­tokines, Syn­thekine has land­ed a $107.5 mil­lion Se­ries B …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times